Private Advisor Group LLC Has $606,000 Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Private Advisor Group LLC lowered its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 36.2% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,923 shares of the specialty pharmaceutical company's stock after selling 2,793 shares during the quarter. Private Advisor Group LLC's holdings in Jazz Pharmaceuticals were worth $606,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. CIBC Asset Management Inc increased its stake in Jazz Pharmaceuticals by 5.2% during the 4th quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company's stock worth $243,000 after acquiring an additional 97 shares during the period. UMB Bank n.a. grew its holdings in shares of Jazz Pharmaceuticals by 70.9% during the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company's stock worth $38,000 after purchasing an additional 129 shares in the last quarter. Ellsworth Advisors LLC increased its position in shares of Jazz Pharmaceuticals by 0.4% in the fourth quarter. Ellsworth Advisors LLC now owns 37,962 shares of the specialty pharmaceutical company's stock worth $4,675,000 after purchasing an additional 149 shares during the period. Exchange Traded Concepts LLC raised its stake in Jazz Pharmaceuticals by 2.2% in the fourth quarter. Exchange Traded Concepts LLC now owns 7,045 shares of the specialty pharmaceutical company's stock valued at $868,000 after purchasing an additional 155 shares in the last quarter. Finally, Cooper Financial Group lifted its position in Jazz Pharmaceuticals by 3.7% during the fourth quarter. Cooper Financial Group now owns 4,334 shares of the specialty pharmaceutical company's stock worth $534,000 after purchasing an additional 156 shares during the period. Institutional investors own 89.14% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several equities analysts have commented on the stock. TD Cowen decreased their target price on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating on the stock in a report on Thursday, November 7th. JPMorgan Chase & Co. increased their price target on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. HC Wainwright restated a "buy" rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Piper Sandler reaffirmed an "overweight" rating and issued a $176.00 target price (up previously from $163.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, February 26th. Finally, Morgan Stanley upgraded Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $140.00 to $175.00 in a research note on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $184.47.

Insider Buying and Selling

In other news, EVP Neena M. Patil sold 3,800 shares of the company's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $144.87, for a total value of $550,506.00. Following the sale, the executive vice president now directly owns 33,318 shares of the company's stock, valued at approximately $4,826,778.66. This represents a 10.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Bruce C. Cozadd sold 6,500 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $144.25, for a total transaction of $937,625.00. Following the sale, the chief executive officer now owns 464,058 shares of the company's stock, valued at approximately $66,940,366.50. This trade represents a 1.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 18,113 shares of company stock valued at $2,551,834 over the last ninety days. 4.20% of the stock is owned by company insiders.

Jazz Pharmaceuticals Trading Down 3.2 %

NASDAQ JAZZ traded down $4.49 on Thursday, hitting $135.74. The company's stock had a trading volume of 436,782 shares, compared to its average volume of 733,246. The company's 50-day moving average is $127.64 and its 200 day moving average is $119.71. The firm has a market cap of $8.24 billion, a PE ratio of 19.14, a PEG ratio of 1.04 and a beta of 0.56. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $148.06. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.